ID   KHOS-240S
AC   CVCL_2544
SY   KHOS240S; 240S
DR   BTO; BTO:0003923
DR   CLO; CLO_0007098
DR   EFO; EFO_0002219
DR   CLDB; cl3028
DR   ArrayExpress; E-MTAB-38
DR   ATCC; CRL-1545
DR   cancercelllines; CVCL_2544
DR   CCTCC; GDC0254
DR   CLS; 300433
DR   Cosmic; 1074392
DR   ECACC; 86112810
DR   GEO; GSM186426
DR   GEO; GSM186427
DR   GEO; GSM827381
DR   GEO; GSM1676358
DR   GEO; GSM1701688
DR   IGRhCellID; KHOS240S
DR   LINCS_LDP; LCL-1426
DR   Progenetix; CVCL_2544
DR   Wikidata; Q54899909
RX   PubMed=62397;
RX   PubMed=2233717;
RX   PubMed=2978869;
RX   PubMed=20215515;
RX   PubMed=26351324;
RX   PubMed=28196595;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line).
CC   Transformant: NCBI_TaxID; 11808; Kirsten murine sarcoma virus (Ki-MSV).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Derived from site: In situ; Bone, right femur; UBERON=UBERON_0000981.
ST   Source(s): ATCC; CLS; ECACC
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 10,13
ST   D18S51: 14,17
ST   D21S11: 31.2,32.2
ST   D3S1358: 15
ST   D5S818: 13
ST   D7S820: 11,12
ST   D8S1179: 11,14
ST   FGA: 24
ST   Penta D: 9,10
ST   Penta E: 7,12
ST   TH01: 6
ST   TPOX: 11
ST   vWA: 18
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2546 ! KHOS/NP
SX   Female
AG   13Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   PubMed=62397; DOI=10.1126/science.62397;
RA   Cho H.Y., Cutchins E.C., Rhim J.S., Huebner R.J.;
RT   "Revertants of human cells transformed by murine sarcoma virus.";
RL   Science 194:951-953(1976).
//
RX   PubMed=2233717; DOI=10.1128/mcb.10.11.5772-5781.1990;
RA   Diller L., Kassel J., Nelson C.E., Gryka M.A., Litwak G., Gebhardt M.,
RA   Bressac B., Ozturk M., Baker S.J., Vogelstein B., Friend S.H.;
RT   "p53 functions as a cell cycle control protein in osteosarcomas.";
RL   Mol. Cell. Biol. 10:5772-5781(1990).
//
RX   PubMed=2978869;
RA   Ehrhart J.-C., Duthu A., Ullrich S., Appella E., May P.;
RT   "Specific interaction between a subset of the p53 protein family and
RT   heat shock proteins hsp72/hsc73 in a human osteosarcoma cell line.";
RL   Oncogene 3:595-603(1988).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//